Comparing 2 hypotheses side-by-side
## Mechanistic Overview Complement C1q Mimetic Decoy Therapy starts from the claim that modulating C1QA within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The complement component 1q (C1q) represents a critical molecular bridge between innate immunity and synaptic plasticity in the central nervous system. C1q is a hexameric glycoprotein composed of three distinct polypeptide chains (C1qA,
Prolonged anesthesia triggers complement activation (C1q/C3) that drives microglia-mediated synaptic elimination with projection-specific vulnerability. We hypothesize that ventral hippocampal neurons projecting to prefrontal cortex and amygdala lose synapses preferentially (mediating anxiety through disrupted top-down emotional regulation), while dorsal hippocampal neurons projecting to entorhinal cortex lose synapses preferentially (mediating cognitive deficits through impaired spatial memory
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Complement C1q Mimetic Decoy T | Projection-specific vulnerabil |
|---|---|---|
| Mechanistic | 0.750 | 0.810 |
| Evidence | 0.680 | 0.680 |
| Novelty | 0.820 | 0.720 |
| Feasibility | 0.620 | 0.780 |
| Impact | 0.780 | 0.000 |
| Druggability | 0.580 | 0.000 |
| Safety | 0.650 | 0.000 |
| Competition | 0.850 | 0.000 |
| Data | 0.720 | 0.000 |
| Reproducible | 0.580 | 0.000 |
| KG Connect | 0.728 | 0.500 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
4 rounds · quality: 0.83
Based on the knowledge gap regarding how complement-mediated synaptic elimination in the hippocampus produces both cognitive deficits and anxiety-like behaviors, here are my novel therapeutic hypothes...
Now I'll provide my critical evaluation based on the available evidence: ## Critical Evaluation of Therapeutic Hypotheses ### **Hypothesis 1: Circuit-Specific Complement Targeting** **Specific Weak...
## PRACTICAL FEASIBILITY ASSESSMENT Based on my analysis of the provided hypotheses and literature, here's my assessment of druggability and commercial viability: ## **HYPOTHESIS 6: TEMPORAL COMPLEM...
```json { "ranked_hypotheses": [ { "title": "Temporal Complement Activation Windows", "description": "Cognitive and anxiety phenotypes emerge from different temporal phases of comple...
Curated mechanism pathway diagrams from expert analysis
graph TD
subgraph Disease["Pathological State"]
A["Neurodegeneration Trigger"] -->|"upregulates"| B["C1QA Gene Expression"]
B -->|"produces"| C["C1q Hexameric Complex"]
C -->|"binds to"| D["Synaptic Eat-Me Signals"]
D -->|"includes"| E["Phosphatidylserine and Amyloid-beta"]
C -->|"activates"| F["Classical Complement Cascade"]
F -->|"generates"| G["C3 Convertase Formation"]
G -->|"produces"| H["C3b Opsonization"]
H -->|"recruits"| I["Microglial CR3 Receptors"]
I -->|"triggers"| J["Synaptic Phagocytosis"]
end
subgraph Therapy["C1q Mimetic Decoy Intervention"]
K["C1q Mimetic Decoy Molecule"] -->|"competes with"| C
K -->|"blocks"| D
L["Therapeutic Administration"] -->|"delivers"| K
M["Decoy Sequestration"] -->|"prevents"| F
end
subgraph Outcome["Clinical Endpoints"]
N["Synaptic Preservation"] -->|"maintains"| O["Cognitive Function"]
P["Reduced Neuroinflammation"] -->|"improves"| Q["Neurological Outcomes"]
R["Biomarker Monitoring"] -->|"tracks"| N
end
K -->|"reduces"| J
M -->|"leads to"| N
M -->|"results in"| P
style A fill:#ef5350,stroke:#333,color:#000
style B fill:#ce93d8,stroke:#333,color:#000
style C fill:#ef5350,stroke:#333,color:#000
style D fill:#ef5350,stroke:#333,color:#000
style E fill:#ef5350,stroke:#333,color:#000
style F fill:#ef5350,stroke:#333,color:#000
style G fill:#4fc3f7,stroke:#333,color:#000
style H fill:#4fc3f7,stroke:#333,color:#000
style I fill:#ef5350,stroke:#333,color:#000
style J fill:#ef5350,stroke:#333,color:#000
style K fill:#81c784,stroke:#333,color:#000
style L fill:#81c784,stroke:#333,color:#000
style M fill:#81c784,stroke:#333,color:#000
style N fill:#ffd54f,stroke:#333,color:#000
style O fill:#ffd54f,stroke:#333,color:#000
style P fill:#ffd54f,stroke:#333,color:#000
style Q fill:#ffd54f,stroke:#333,color:#000
style R fill:#4fc3f7,stroke:#333,color:#000